Healthcare industry

Press release - 30/05/2012

Valuable Discussions at the Third International DDI Workshop

The organisation team of the Third International DDI (drug-drug interactions) Workshop has expressed great satisfaction with the course of the scientific meeting. The participants of the DDI Workshop commended the very high scientific level of the presentations and valuable and inspiring discussions of the different topics. Without a doubt, the DDI Workshop at Marbach Castle is a well established platform for the annual exchange between experts,…

The new drug screening and safety pharmacology laboratory at NMI Technologie Transfer GmbH NMI TT GmbH in Reutlingen with its standardised and special test systems complies fully with the requirements of safety pharmacology tests.

Press release - 19/11/2009

TET Systems and Novo Nordisk sign license agreement

TET Systems Holding GmbH & Co. KG (“TET Systems”), a worldwide leader in controlled gene expression, today announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.

The Early Discovery department of the research-based pharmaceutical company Nycomed GmbH deals with early drug research from the identification of targets to the generation of lead structures. This process involves high-throughput drug screening. On behalf of www.bio-pro.de Michael Statnik talked with Dr. Stefanie Polej about the process of the automated analysis of molecule activities in the Constance-based company.

Dr. Pitter Huesgen Dr. Michael Strerath and Dr. Carl Kübler have been awarded this years Nycomed Award. The Award which is worth a total of 15000 distinguishes outstanding doctoral theses in the fields of biology chemistry and physics.

Article - 04/02/2013

DKFZ-HIPO – the Heidelberg Center for Personalised Oncology

The German Cancer Research Center (DKFZ) and the National Center for Tumour Diseases (NCT) have jointly initiated the Heidelberg Center for Personalised Oncology (HIPO) which provides cancer patients with high-throughput genetic and molecular analyses. In anticipation of the upcoming World Cancer Day on 4th February 2013, the potential of high-throughput genetic and molecular analyses in improving cancer therapy was presented at a workshop held…

Organisers and more than 300 participants were very enthusiastic about the European BioFine life sciences congress recently held in Freiburg. Four different life sciences conferences were organised . Freiburg will also host BioFine 2009.

Press release - 29/06/2009

Research Prize for Clinical Pharmacology in Ulm

Julia Kirchheiner, a professor of Clinical Pharmacology at the Institute of Natural Medicine and Clinical Pharmacology, University of Ulm, in Germany, was awarded the Utrecht Award for Excellence in Pharmaceutical Research, 2009. The international prize is awarded once every two years to non-University of Utrecht scientists who have a proven record over years of excellent research vision and leadership of improving drug therapy or safety.

Press release - 04/05/2011

Vetter’s Chicago Facility Now Accepting Projects

Vetter, a leading provider of aseptic prefilled drug-delivery systems, announced that its Chicago facility is accepting client projects. Located at the Illinois Science + Technology Park in Skokie, Illinois, the site supports preclinical through phase II products.

Press release - 25/06/2010

Vetter to invest further millions in the construction of a modern centre for visual inspection and logistics in Ravensburg

Ravensburg-based Vetter is expanding further. Last Friday, Vetter, a specialist in aseptically pre-filled drug-delivery systems, held a ceremony to break the ground for the construction of a new centre for visual inspection and logistics. Together with representatives from politics and industry, the company’s executives broke the ground for the new facility, which is estimated to cost more than 30 million euros. The construction of the new centre…

Article - 15/03/2010

Campaign to eradicate malaria

After many decades, efforts to develop an effective vaccine against malaria have finally brought researchers closer to their goal. However, the goal of eradicating malaria completely can only be reached through a complex strategy, to which researchers from Heidelberg are making intensive contributions.

Germans like natural solutions and show a marked preference for medicines made from St. John’s wort, valerian, devil’s claw or Marian Thistle. However, when taking herbal medicines people are well advised to be cautious: "herbal" does not automatically mean safe, warns Thomas Simmet, pharmacologist from the University Hospital of Ulm.

Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents.

Article - 11/02/2013

Quality management: burden or opportunity?

Companies are facing increasing demands. Globalisation and an increasingly quality-conscious market increase competition and pricing pressure. To remain globally competitive companies need a product and service quality that will satisfy the customer in the long term. Alexander Cansier managing director of OrgaConnect GmbH has specialised in the support of small and medium-sized companies in the life sciences pharmaceutical and medical technology…

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.

Press release - 19/01/2010

Affimed Therapeutics AG Completes Move Into Drug Development

Affimed Therapeutics AG, the therapeutic antibody company from Heidelberg, announced today that it is now concentrating all activities on the exclusive development of its in-house drug candidates derived from the company's proprietary TandAb technology platform. In line with this, the Company has spun-out its antibody discovery activities into a new company: AbCheck s.r.o, (Plzen, Czech Republic).

Strasbourg, France based NovAliX SAS today announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH of Heidelberg, Germany, a leading fragment based drug discovery services company. Financial details of the transaction were not disclosed.

Press release - 08/08/2012

Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial

The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…

Article - 07/01/2014

BioMed X GmbH - An innovation centre in Heidelberg at the interface between academia and industry

BioMed X GmbH, founded in Heidelberg in March 2013, and Merck KGaA from Darmstadt have established a new way of fostering innovation at the interface of academic biomedical research and pharmaceutical industry-based research. Teams of top young and talented scientists from leading academic institutions worldwide carry out product-oriented research and development projects that are funded by the industry and for which they receive guidance from…

Article - 15/03/2010

The first active immunisations against cancer

The first anti-cancer vaccines were developed to prevent women from becoming infected with papillomaviruses and to protect them against cervical cancer. The development of vaccines can be traced back to the work of Nobel Laureate Harald zur Hausen and his colleagues at the German Cancer Research Centre in Heidelberg. But more development is required in the field of anti-cancer vaccines and this is why researchers worldwide are working on vaccines…

Article - 17/12/2012

Medicyte GmbH – gold standard for human cells

Medicyte GmbH is a life sciences company located in the city of Heidelberg. It focuses primarily on the production of quasi-primary human cells of the highest quality and in virtually unlimited quantity. MediCyte’s goal is to establish its proprietary cell proliferation technologies as gold standard for the use of human cells and cell products in research, development and cell therapy.

Vaccine development - 25/05/2021

Vaccines – a beacon of hope in the fight against pandemics

Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology. The development of much-needed vaccines against many other…

Expert interview - 16/01/2019

Cybersecurity is an important issue for the pharmaceutical industry

In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.

Article - 14/02/2011

A molecule that enables local virus defence

Dr. Markus Mordstein has spent the last four years as a doctoral student at the University of Freiburg investigating the previously relatively unknown interferon lambda. He has been able to show that this molecule has similar protective functions to type I interferons and he has also found that it is far more selective in terms of the site where it exerts its effect.

Article - 29/05/2012

Intestinal bacteria and human gut types

The type of bacteria that colonize the human gut does not just influence our digestion and well-being. Metagenome sequencing has provided an international consortium involving scientists from the European Molecular Biology Laboratory at the University Hospital of Heidelberg with evidence that certain individuals have different gut types with different types of bacteria. Such individuals not only differ in their predisposition to disease, but also…